RÉSUMÉ
Pituitary adenomas are uncommon, difficult to diagnose tumors whose heterogeneity and low incidence complicate large-scale studies. The Molecular Registry of Pituitary Adenomas (REMAH) was promoted by the Andalusian Society of Endocrinology and Nutrition (SAEN) in 2008 as a cooperative clinical-basic multicenter strategy aimed at improving diagnosis and treatment of pituitary adenomas by combining clinical, pathological, and molecular information. In 2010, the Spanish Society of Endocrinology and Nutrition (SEEN) extended this project to national level and established 6 nodes with common protocols and methods for sample and clinical data collection, molecular analysis, and data recording in a common registry (www.remahnacional.com). The registry combines clinical data with molecular phenotyping of the resected pituitary adenoma using quantitative real-time PCR of expression of 26 genes: Pituitary hormones (GH-PRL-LH-FSH-PRL-ACTH-CGA), receptors (somatostatin, dopamine, GHRH, GnRH, CRH, arginine-vasopressin, ghrelin), other markers (Ki67, PTTG1), and control genes. Until 2015, molecular information has been collected from 704 adenomas, out of 1179 patients registered. This strategy allows for comparative and relational analysis between the molecular profile of the different types of adenoma and the clinical phenotype of patients, which may provide a better understanding of the condition and potentially help in treatment selection. The REMAH is therefore a unique multicenter, interdisciplinary network founded on a shared database that provides a far-reaching translational approach for management of pituitary adenomas, and paves the way for the conduct of combined clinical-basic innovative studies on large patient samples.
Sujet(s)
Adénomes/épidémiologie , Endocrinologie/organisation et administration , Tumeurs de l'hypophyse/épidémiologie , Médecine de précision/tendances , Enregistrements , /tendances , Adénomes/composition chimique , Adénomes/génétique , Adolescent , Adulte , Sujet âgé , Enfant , Bases de données factuelles , Endocrinologie/tendances , Femelle , Analyse de profil d'expression de gènes , Études d'associations génétiques , Humains , Mâle , Adulte d'âge moyen , Biologie moléculaire , Protéines tumorales/analyse , Protéines tumorales/génétique , Hormones hypophysaires/analyse , Hormones hypophysaires/génétique , Tumeurs de l'hypophyse/composition chimique , Tumeurs de l'hypophyse/génétique , ARN tumoral/génétique , Réaction de polymérisation en chaine en temps réel , Récepteur hormone hypophysaire/analyse , Récepteur hormone hypophysaire/génétique , Sociétés médicales , Espagne/épidémiologie , Jeune adulteSujet(s)
Dépression/traitement médicamenteux , Récepteurs couplés aux protéines G/métabolisme , Animaux , Humains , Hormones hypothalamiques/antagonistes et inhibiteurs , Ligands , Mélanines/antagonistes et inhibiteurs , Souris , Souris knockout , Hormones hypophysaires/antagonistes et inhibiteurs , Récepteur hormone hypophysaire/analyseRÉSUMÉ
INTRODUCTION: Melanin concentrating hormone is an orexigenic hypothalamic neuropeptide, which plays an important role in the complex regulation of energy balance and body weight mediated by the melanin concentrating hormone receptor subtype 1 (MCH1). Compelling pharmacological evidence implicating MCH1 signaling in the regulation of food intake and energy expenditure has generated a great deal of interest by pharmaceutical companies as MCH1 antagonists may have potential therapeutic benefit in the treatment of obesity and metabolic syndrome. METHODS: Although radioligand receptor binding assay has been one of the most powerful tools for receptor research and drug discovery, the limitations of radioisotopes and the problems related to safety and waste disposal limits their application in high throughput screening and has led to a growing interest in alternative, nonradioactive technologies. To develop a sensitive and reproducible assay system for MCH1, the time-resolved fluorescence (TRF) receptor binding assay with AcroWell filter plates was tested and validated. RESULTS: Comparing to the radioligand receptor binding assay for MCH1, the TRF assay presented higher Z/Z' factors with the lower signal-to-noise ratio. The known high-affinity MCH1 receptor antagonist, SNAP-7941, exhibited an IC50 value of 1.66+/-0.10 nM that is very similar to the IC50 value of MCH in a radioligand binding assay with an excellent correlation coefficient (0.9884). DISCUSSION: These results suggest that our TRF receptor binding assay for MCH1 can achieve the desired sensitivity and reproducibility to replace the radioligand receptor assay in a fluorometric system that can be developed for high throughput screening.
Sujet(s)
Fluorimétrie/méthodes , Mélanines/antagonistes et inhibiteurs , Pipéridines/pharmacologie , Pyrimidines/pharmacologie , Récepteur hormone hypophysaire/antagonistes et inhibiteurs , Récepteur hormone hypophysaire/analyse , Animaux , Dosage biologique , Relation dose-effet des médicaments , Humains , Concentration inhibitrice 50 , Ligands , Mélanines/génétique , Mélanines/physiologie , Souris , Dosage par compétition , Rats , Récepteur hormone hypophysaire/génétique , Récepteur hormone hypophysaire/métabolisme , Reproductibilité des résultats , Sensibilité et spécificité , Facteurs tempsRÉSUMÉ
Mesotocin, an oxytocin-like peptide, is released in highest concentrations during parturition in macropodid marsupials. In late pregnant wallabies, uterine sensitivity to mesotocin increases markedly in the myometrium of the gravid uterus. This coincides with a significant increase in myometrial mesotocin receptor concentrations 3-4 days before term. To date, there is no information on mesotocin receptor gene expression in female wallaby reproductive tissues. This study aimed to examine mesotocin receptor gene expression in the uterus and ovaries of pregnant tammar wallabies, and to localise mesotocin receptors within the uterus. An RT-PCR strategy produced a consensus nucleotide sequence of 834 bp, which encoded 278 amino acids of transmembrane domains I to VI. This protein sequence has approximately 80% homology with the bovine and rat oxytocin receptor exon 2 region. Only one mesotocin receptor was detected in the tammar genome. The myometrium and mammary gland both expressed a 4.1 kb mesotocin receptor gene transcript. Myometrial mesotocin receptor gene expression increased on day 22 of the 26-day gestation and was significantly higher in the gravid than the non-gravid uterus in late pregnancy. This pattern of mesotocin receptor gene expression paralleled mesotocin receptor concentrations. Mesotocin binding sites were localised only to the myometrium, the highest densities being observed in the gravid uterus. Finally, this study showed high expression of mesotocin receptors in the corpus luteum. The pattern of luteal mesotocin receptor expression differed from the myometrium, with a decrease in mesotocin receptors occurring on the day of expected births.
Sujet(s)
Macropodidae/métabolisme , Ovaire/métabolisme , Gestation animale/métabolisme , ARN messager/analyse , Récepteur hormone hypophysaire/génétique , Utérus/métabolisme , Séquence d'acides aminés , Animaux , Autoradiographie , Sites de fixation , Fixation compétitive , Technique de Northern/méthodes , Technique de Southern/méthodes , Corps jaune/composition chimique , Corps jaune/métabolisme , Femelle , Expression des gènes , Humains , Glandes mammaires animales/composition chimique , Glandes mammaires animales/métabolisme , Données de séquences moléculaires , Myomètre/composition chimique , Myomètre/métabolisme , Ovaire/composition chimique , Grossesse , Dosage par compétition/méthodes , Récepteur hormone hypophysaire/analyse , RT-PCR , Alignement de séquences , Ovis , Utérus/composition chimiqueRÉSUMÉ
Somatolactin (SL) is a pituitary hormone of the GH/prolactin (PRL) family that so far has been found only in fish. Compared with GH and PRL, the primary structure of SL is highly conserved among divergent fish species, suggesting it has an important function and a discriminating receptor that constrains structural change. However, SL functions are poorly understood, and receptors for SL have not yet been identified. During cloning of GH receptor cDNA from salmon, we found a variant with relatively high (38-58%) sequence identity to vertebrate GH receptors and low (28-33%) identity to PRL receptors; however, the recombinant protein encoding the extracellular domain showed only weak binding of GH. Ligand binding of the recombinant extracellular domain for this receptor confirmed that the cDNA encoded a specific receptor for SL. The SL receptor (SLR) has common features of a GH receptor including FGEFS motif, six cysteine residues in the extracellular domain, a single transmembrane region, and Box 1 and 2 regions in the intracellular domain. These structural characteristics place the SLR in the cytokine receptor type I homodimeric group, which includes receptors for GH, PRL, erythropoietin, thrombopoietin, granulocyte-colony stimulating factor, and leptin. Transcripts for SLR were found in 11 tissues with highest levels in liver and fat, supporting the notion that a major function of SL is regulation of lipid metabolism. Cloning SLR cDNA opens the way for discovery of new SL functions and target tissues in fish, and perhaps novel members of this receptor family in other vertebrates.
Sujet(s)
Glycoprotéines , Oncorhynchus , Hormones hypophysaires , Récepteur hormone hypophysaire/analyse , Séquence d'acides aminés , Animaux , Séquence nucléotidique , Clonage moléculaire , ADN complémentaire/composition chimique , ADN complémentaire/génétique , Escherichia coli , Femelle , Protéines de poisson , Expression des gènes , Mâle , Données de séquences moléculaires , Phylogenèse , Récepteur hormone hypophysaire/composition chimique , Récepteur hormone hypophysaire/génétique , Récepteur prolactine/composition chimique , Récepteur STH/composition chimique , Protéines recombinantes , RT-PCR , Similitude de séquences , Distribution tissulaireRÉSUMÉ
The suprachiasmatic nucleus (SCN) contains the predominant circadian pacemaker in mammals. Considerable evidence indicates that VPAC(2) and PAC(1), receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP), play critical roles in maintaining and entraining circadian rhythms. Retinal projections to the rat SCN contain PACAP and terminate mostly in the ventral SCN, the site of VIP neurons. The incidence of VPAC(2) and PAC(1) mRNAs within distinct neuronal populations of the rat SCN has been determined using double-label in situ hybridization. VPAC(2) mRNA was detected in almost all arginine-vasopressin (AVP) neurons of the dorsomedial SCN and in 41% of the VIP neurons; somatostatin (SST) neurons, predominantly in dorsomedial and intermediate regions, showed a decreased incidence (23%). PAC(1) mRNA was present in nearly half of the VIP and SST neurons (45% and 40%, respectively) and in one-third of the AVP neurons (32%). Cells expressing VPAC(2) mRNA also were detected in diencephalic areas that receive VIP-immunoreactive SCN efferents, such as the peri-suprachiasmatic region, lateral subparaventricular zone, parvocellular hypothalamic paraventricular subdivisions, dorsomedial hypothalamic nucleus, and anterior thalamic paraventricular and paratenial nuclei. The extensive distribution of PAC(1) mRNA within the SCN suggests that actions of PACAP are not restricted to the predominantly retinorecipient region. The presence of VPAC(2) mRNA in nearly half the VIP neurons, in almost all the AVP neurons, and at sites receiving VIP-immunoreactive SCN efferents suggests that the SCN VIP neurons are coupled and/or autoregulated and also influence the AVP-containing dorsomedial SCN and distal sites via VPAC(2).
Sujet(s)
Biosynthèse des peptides , ARN messager/biosynthèse , Récepteur hormone hypophysaire/biosynthèse , Récepteur peptide intestinal vasoactif/biosynthèse , Noyau suprachiasmatique/métabolisme , Peptide vasoactif intestinal/métabolisme , Animaux , Voies efférentes/composition chimique , Voies efférentes/métabolisme , Régulation de l'expression des gènes/physiologie , Mâle , Biosynthèse des peptides/physiologie , ARN messager/analyse , Rats , Rat Wistar , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Récepteur hormone hypophysaire/analyse , Récepteur peptide intestinal vasoactif/analyse , Récepteur au peptide intestinal vasoactif (VIP) et au PACAP , Noyau suprachiasmatique/composition chimique , Peptide vasoactif intestinal/analyseRÉSUMÉ
Chronic obstructive pulmonary disease is a major clinical disorder usually associated with cigarette smoking. A central feature of chronic obstructive pulmonary disease is inflammation coexisting with an abnormal protease/antiprotease balance, leading to apoptosis and elastolysis. In an in vitro study of rat lung alveolar L2 cells, cigarette smoke extract (CSE) induced apoptotic cell death. Exposure of L2 cells to CSE at a concentration of 0.25% resulted in a 50% increase of caspase-3 and matrix metalloproteinase (MMP) activities. Specific inhibitors for caspases and MMPs attenuated the cytotoxicity of CSE. RT-PCR amplification identified VPAC2 receptors in L2 cells. A radioligand-binding assay with (125)I-labeled vasoactive intestinal peptide (VIP) found high affinity and saturable (125)I-labeled VIP-binding sites in L2 cells. VIP and pituitary adenylate cyclase-activating polypeptide (PACAP27) were approximately equipotent for both VIP receptor binding and stimulation of cAMP production in L2 cells. Both neuropeptides, at concentrations higher than 10(-13) m, produced a concentration-dependent inhibition of CSE-induced cell death in L2 cells. VIP, at 10(-7) m, reduced CSE-stimulated MMP activity and caspase-3 activation. The present study has shown that VIP and PACAP27 significantly attenuate the cytotoxicity of CSE through the activation of VPAC2 receptor, and the protective effect of VIP may partly be the result of a reduction in the CSE-induced stimulation of MMPs and caspases.
Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Neuropeptides/pharmacologie , Nicotiana , Alvéoles pulmonaires/effets des médicaments et des substances chimiques , Fumée/effets indésirables , Peptide vasoactif intestinal/pharmacologie , Animaux , Caspase-3 , Caspases/métabolisme , Survie cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Matrix metalloproteinases/métabolisme , Polypeptide activateur de l'adénylcyclase hypophysaire , Alvéoles pulmonaires/anatomopathologie , Broncho-pneumopathie chronique obstructive/étiologie , Rats , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Récepteur hormone hypophysaire/analyse , Récepteur peptide intestinal vasoactif/analyse , Récepteur au peptide intestinal vasoactif (VIP) et au PACAPRÉSUMÉ
Mast cells play a major role in the initiation of inflammation and allergic reactions. As cell numbers are tightly controlled by the interplay of factors affecting cell proliferation, development, and death the regulation of mast cell number may be important. Melanocyte-stimulating hormone inhibits most forms of inflammation by an unknown mechanism. In the present study, we have found that the alpha-melanocyte-stimulating hormone (alpha-MSH) inhibited endotoxin-mediated nuclear transcription factor kappaB (NF-kappaB) activation in different cells correlated with the expression of alpha-MSH receptors. We have also found for the first time that it induces cell death alone or in endotoxin-stimulated mast cells. alpha-MSH-mediated apoptosis was not observed in NF-kappaB overexpressed cells. The inhibitory effect of alpha-MSH was mediated through generation of cAMP, as inhibitors of adenylate cyclase and of protein kinase A reversed its inhibitory effect. Overall, our results suggest that NF-kappaB is the key molecule involved in alpha-MSH-mediated cell death and this may help to regulate mast cell-mediated inflammation.
Sujet(s)
Mastocytes/cytologie , Facteur de transcription NF-kappa B/antagonistes et inhibiteurs , Hormone mélanotrope alpha/pharmacologie , Animaux , Mort cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , AMP cyclique/métabolisme , Endotoxines/pharmacologie , Antienzymes/pharmacologie , Humains , Inflammation/anatomopathologie , Mastocytes/effets des médicaments et des substances chimiques , Mastocytes/métabolisme , Souris , Facteur de transcription NF-kappa B/physiologie , Récepteur hormone hypophysaire/analyseRÉSUMÉ
OBJECTIVES/HYPOTHESIS: Pituitary adenylate cyclase-activating polypeptide (PACAP) has neurotrophic effects of neural regeneration and gives protection to the nervous system. We investigated whether PACAP had a neurotrophic effect on peripheral motoneurons and whether PACAP could facilitate glial cell line-derived neurotrophic factor (GDNF), a neurotrophin, in nerve regeneration. The presence and distribution of PACAP receptors following facial nerve transection were also investigated. STUDY DESIGN: Animal experiment. METHODS: Unilateral transection of the facial nerve was performed in male Hartley guinea pigs, and PACAP was injected at the site. Saline was substituted as a control. Compound muscle action potentials were recorded to measure the changes of latency. Glial cell line-derived neurotrophic factor (GDNF) content in facial target muscle was measured using enzyme-linked immunosorbent assay. The regenerating site was taken for histological studies. RESULTS: Pituitary adenylate cyclase-activating polypeptide hastened the appearance of compound muscle action potentials and shortened the latency. Pituitary adenylate cyclase-activating polypeptide increased and prolonged the nerve transection-induced GDNF increase in the facial muscles. The number of myelinated fibers at 1 to 4 weeks after the transection was increased. PAC1 receptor or VPAC1 receptor or both were identified in the injury area at 2 to 4 weeks. CONCLUSIONS: Pituitary adenylate cyclase-activating polypeptide facilitated the recovery of latency of compound muscle action potentials or the number of myelinated axons, or both. Pituitary adenylate cyclase-activating polypeptide prolonged the GDNF levels in target organs. These data indicated that PACAP promoted regeneration of the facial nerve.
Sujet(s)
Lésions traumatiques du nerf facial/physiopathologie , Régénération nerveuse/effets des médicaments et des substances chimiques , Neuropeptides/pharmacologie , Animaux , Stimulation électrique , Électromyographie/effets des médicaments et des substances chimiques , Potentiels évoqués moteurs/effets des médicaments et des substances chimiques , Muscles de la face/innervation , Nerf facial/effets des médicaments et des substances chimiques , Nerf facial/physiopathologie , Lésions traumatiques du nerf facial/anatomopathologie , Facteur neurotrophique dérivé des cellules gliales , Cochons d'Inde , Mâle , Facteurs de croissance nerveuse/analyse , Régénération nerveuse/physiologie , Polypeptide activateur de l'adénylcyclase hypophysaire , Temps de réaction/effets des médicaments et des substances chimiques , Temps de réaction/physiologie , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Récepteur hormone hypophysaire/analyse , Récepteur peptide intestinal vasoactif/analyse , Récepteur de type I au peptide intestinal vasoactif , Activation chimiqueRÉSUMÉ
Melanin-concentrating hormone (MCH), a cyclic nonadecapeptide, is predominantly expressed in mammalian neurons located in the zona incerta and lateral hypothalamus. Current interest in MCH relates to its role in the control of feeding behaviour. Two receptors for MCH were recently found: MCH-R(1) and MCH-R(2). We show here by RT-PCR analysis and immunofluorescence studies that the human neuroblastoma cell line Kelly expresses MCH and MCH-R(1) but not MCH-R(2). In competition assays using 125I-labelled MCH an inhibitory concentration 50% (IC(50)) of 76nM was determined for MCH, indicating a high affinity of Kelly cells for MCH. MCH induces mitogen-activated protein kinase (MAPK) phosphorylation in Kelly cells but no increase in the intracellular free Ca(2+) concentration. This suggests that MCH signals via Galpha(i)/Galpha(0) in these cells. The presence and functionality of MCH-R(1) renders this neuronal cell a very useful model for future structure-activity studies in a physiological environment mimicking the human brain for the evaluation of potential appetite-regulating drugs.
Sujet(s)
Neurones/composition chimique , Récepteur hormone hypophysaire/analyse , Signalisation calcique , Lignée cellulaire , Technique d'immunofluorescence , Cellules HeLa , Humains , Système de signalisation des MAP kinases , Neuroblastome , ARN messager/biosynthèse , Récepteur hormone hypophysaire/génétique , Récepteur hormone hypophysaire/métabolisme , RT-PCR , Cellules cancéreuses en cultureRÉSUMÉ
Mesotocin, an oxytocin-like peptide, stimulates uterine contractions during marsupial parturition. Female marsupials have two separate uteri, and in monovular species, the uterus with the conceptus is gravid, whereas the contralateral uterus is nongravid. Marsupials are unique because systemic and feto-placental factors in the regulation of uterine function can be differentiated. In pregnant tammar wallabies, a marked increase in myometrial mesotocin receptors (MTRs) occurs on Day 23 of the 26-day gestation, but only in the gravid uterus. The objective of this study was to investigate the effects of removing the conceptus on this MTR up-regulation. Complete fetectomy on Day 20 of gestation resulted in significantly lower MTR mRNA and receptor concentrations on Day 23 compared with sham-operated controls. In contrast, there was no significant difference in MTR expression between controls and partially fetectomized animals in which uterine distension was maintained in the absence of a conceptus. In a related study, we examined MTRs in the myometrium of animals that appeared to be pregnant with a large, distended uterus. However, these uteri contained an abnormally developed fetus and avascular placenta. In these animals, MTR levels were significantly higher in the distended uterus compared with the nondistended uterus, and did not differ from controls. These data demonstrate that uterine occupancy is essential for the marked increase in uterine MTRs observed on Day 23 gestation. It also appears that distension may be one of the key factors involved.
Sujet(s)
Foetus/chirurgie , Macropodidae/physiologie , Myomètre/composition chimique , Récepteur hormone hypophysaire/analyse , Animaux , Endomètre/anatomie et histologie , Endomètre/vascularisation , Femelle , Âge gestationnel , Placenta/chirurgie , Grossesse , ARN messager/analyse , Récepteur hormone hypophysaire/génétique , Utérus/anatomie et histologie , Utérus/composition chimique , Utérus/physiologieRÉSUMÉ
Pituitary adenylate cyclase-activating polypeptide (PACAP) is known to regulate gastric acid secretion and intestinal motility. In the present study, the pattern of distribution of PACAP and PACAP type 1 receptor (PAC1) immunoreactivities were examined in the rat stomach and distal colon using a specific polyclonal antibody raised against rat/human PAC1. Western blot of the membrane preparations of NIH/3T3 cells transfected with the human PAC1 obtained by using rabbit polyclonal anti-PAC1 antibody showed a protein band with a molecular mass of approximately 50 kDa. NIH/3T3 cells transfected with the human PAC1 and incubated with the anti-PAC1 antibody displayed surface cell-type immunoreactivity, which was internalized following ligand exposure. In gastric or colonic longitudinal muscle/myenteric plexus (LMMP) whole mount preparations as well as cryostat sections, PACAP immunoreactivity was observed in cell bodies within the myenteric ganglia and nerve fibers in the muscle layers and mucosa. PAC1 immunoreactivity was confined mainly on the surface of the nerve cells. PACAP and PAC1 immunoreactivities showed a similar pattern of distribution in gastric and colonic tissues. Adjacent sections or LMMP whole mount preparations labeled with protein gene product 9.5 (PGP 9.5) revealed the neuronal identity of myenteric cells bearing PAC1. The neuronal localization of PACAP and PAC1 receptors supports their role in the neural regulation of gastric acid secretion and gastrointestinal motor function.
Sujet(s)
Côlon/composition chimique , Côlon/innervation , Système nerveux entérique/composition chimique , Muqueuse gastrique/composition chimique , Muqueuse gastrique/innervation , Neurones/composition chimique , Neuropeptides/analyse , Récepteur hormone hypophysaire/analyse , Cellules 3T3 , Animaux , Technique de Western , Système nerveux entérique/cytologie , Expression des gènes , Immunohistochimie , Mâle , Souris , Plexus myentérique/composition chimique , Plexus myentérique/cytologie , Polypeptide activateur de l'adénylcyclase hypophysaire , Rats , Rat Sprague-Dawley , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Thiolester hydrolases/analyse , Ubiquitin thiolesteraseRÉSUMÉ
Maturation of the fetal pituitary and adrenal glands allows the secretion of cortisol, which in turn leads to an increase in prostaglandin and mesotocin production. The production of prostaglandin and mesotocin results in an increase in uterine contractions and initiates birth in marsupials. The major metabolite of PGF(2alpha), 13,14-dihydro-15-keto-prostaglandin F(2alpha) (PGFM), has been found in the plasma of the possum at the time of birth and administration of PGF(2alpha) to female possums induced the adoption of the birth position. Evidence that mesotocin is an integral hormone of birth in the tammar wallaby indicates that both PGF(2alpha) and mesotocin or oxytocin are required for marsupial birth. The presence of PGF(2alpha) receptors in the uterus and corpus luteum of the possum, and the in vitro uterine responsiveness to PGF(2alpha) or oxytocin, were examined. PGF(2alpha) receptors were not observed in possum uteri and the inability of PGF(2alpha) to cause contractions indicates that PGF(2alpha) is not involved directly in contraction of the uterus at parturition. The presence of oxytocin and mesotocin receptors in the uterus of possoms and the ability of oxytocin to induce uterine contraction in vitro supports the view that mesotocin is required for expulsion of the young from the uterus. Low numbers of PGF(2alpha) receptors were found in the possum corpus luteum at birth, indicating an involvement of PGF(2alpha) in regression of the corpus luteum.
Sujet(s)
Dinoprost/pharmacologie , Opossum/physiologie , Ocytocine/pharmacologie , Contraction utérine/effets des médicaments et des substances chimiques , Animaux , Corps jaune/composition chimique , Femelle , Techniques in vitro , Grossesse , Dosage par compétition/méthodes , Récepteurs à l'ocytocine/analyse , Récepteur hormone hypophysaire/analyse , Récepteur prostaglandine/analyse , Utérus/composition chimique , Utérus/effets des médicaments et des substances chimiquesRÉSUMÉ
AequoScreen, a cellular aequorin-based functional assay, has been optimized for luminescent high-throughput screening (HTS) of G protein-coupled receptor (GPCRs). AequoScreen is a homogeneous assay in which the cells are loaded with the apoaequorin cofactor coelenterazine, diluted in assay buffer, and injected into plates containing the samples to be tested. A flash of light is emitted following the calcium increase resulting from the activation of the GPCR by the sample. Here we have validated a new plate reader, the Hamamatsu Photonics FDSS6000, for HTS in 96- and 384-well plates with CHO-K1 cells stably coexpressing mitochondrial apoaequorin and different GPCRs (AequoScreen cell lines). The acquisition time, plate type, and cell number per well have been optimized to obtain concentration-response curves with 4000 cells/well in 384-well plates and a high signal:background ratio. The FDSS6000 and AequoScreen cell lines allow reading of twenty 96- or 384-well plates in 1 h with Z' values of 0.71 and 0.78, respectively. These results bring new insights to functional assays, and therefore reinforce the interest in aequorin-based assays in a HTS environment.
Sujet(s)
Aequorine/analyse , Aequorine/composition chimique , Biotechnologie/méthodes , Spectrométrie de fluorescence/méthodes , Animaux , Automatisation , Biotechnologie/instrumentation , Cellules CHO , Cricetinae , Relation dose-effet des médicaments , Humains , Ligands , Récepteurs des orexines , Photons , Récepteur de la sérotonine de type 5-HT2B , Récepteurs couplés aux protéines G , Récepteur aux neuropeptides/analyse , Récepteur hormone hypophysaire/analyse , Récepteurs sérotoninergiques/analyse , Sensibilité et spécificité , Spectrométrie de fluorescence/instrumentation , Facteurs tempsRÉSUMÉ
New receptor-avid radiotracers are being developed for site-specific in vivo targeting of a myriad of receptors expressed on cancer cells. This review exemplifies strategies being used to design radiometallated peptide conjugates that maximize uptake in tumors and optimize their in vivo pharmacokinetic properties. Efforts to produce synthetic peptide analogues that target the following three receptor systems are highlighted: Gastrin releasing peptide (GRP), alpha-melanocyte stimulating hormone (alpha-MSH), and guanylate cyclase-C (GC-C) receptors.
Sujet(s)
Guanylate cyclase , Tumeurs/imagerie diagnostique , Radiopharmaceutiques , Récepteur bombésine/analyse , Récepteurs de surface cellulaire/analyse , Récepteurs peptidiques , Récepteur hormone hypophysaire/analyse , Animaux , Humains , Mélanome/imagerie diagnostique , Mélanome/thérapie , Tumeurs/composition chimique , Scintigraphie , Récepteurs des entérotoxines , Récepteurs à activité guanylate cyclaseRÉSUMÉ
Melanin-concentrating hormone (MCH) is a neuropeptide highly expressed in the brain that regulates several physiological functions mediated by receptors in the G protein-coupled receptor family. Recently an orphan receptor, SLC-1, has been identified as an MCH receptor (MCH-R1). Herein we identify and characterize a novel receptor for human MCH (MCH-R2). The receptor is composed of 340 amino acids encoded by a 1023-base pair cDNA and is 35% homologous to SLC-1. (125)I-MCH specifically bound to Chinese hamster ovary cells stably expressing MCH-R2. MCH stimulated dose-dependent increases in intracellular free Ca(2+) and inositol phosphate production in these cells but did not affect cAMP production. The pharmacological profile for mammalian MCH, [Phe(13),Tyr(19)]MCH, and salmon MCH at MCH-R2 differed compared with MCH-R1 as assessed by intracellular signaling and radioligand binding assays. The EC(50) in signaling assays and the IC(50) in radioligand binding assays of salmon MCH was an order of magnitude higher than mammalian MCH at MCH-R2. By comparison, the EC(50) and IC(50) values of salmon MCH and mammalian MCH at MCH-R1 were relatively similar. Blot hybridization revealed exclusive expression of MCH-R2 mRNA in several distinct brain regions, particularly in the cortical area, suggesting the involvement of MCH-R2 in the central regulation of MCH-mediated functions.
Sujet(s)
Récepteur hormone hypophysaire/analyse , Séquence d'acides aminés , Animaux , Séquence nucléotidique , Cellules CHO , Calcium/métabolisme , Cricetinae , Inositol phosphates/métabolisme , Données de séquences moléculaires , ARN messager/analyse , Récepteur hormone hypophysaire/génétique , Récepteur hormone hypophysaire/métabolismeRÉSUMÉ
It appears that PACAP has a direct action on somatotrophs to release GH. The intracellular signal transduction mechanisms for PACAP might be similar to but partly distinct from those for GRH. PACAP might play a role in GH secretion induced by serotoninergic mechanisms but not in ultradian rhythm of GH secretion in the rat. PACAP can stimulate PRL release from the pituitary in rats possibly through indirect paracrine effect. In addition, PACAP might participate in regulation of PRL secretion via hypothalamic VIP.
Sujet(s)
Hormone de croissance/métabolisme , Neuropeptides/physiologie , Adénomes/métabolisme , Animaux , Cellules cultivées , Humains , Hypothalamus/composition chimique , Hypothalamus/effets des médicaments et des substances chimiques , Hypothalamus/physiologie , Neuropeptides/analyse , Neuropeptides/pharmacologie , Polypeptide activateur de l'adénylcyclase hypophysaire , Hypophyse/composition chimique , Hypophyse/effets des médicaments et des substances chimiques , Hypophyse/physiologie , Tumeurs de l'hypophyse/métabolisme , Prolactine/métabolisme , Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire , Récepteur hormone hypophysaire/analyse , Récepteur hormone hypophysaire/physiologieRÉSUMÉ
In order to transfect melanoma specifically by receptor-mediated endocytosis we prepared dioctadecyl aminoglycylspermine (lipospermine)--DNA complexes with [Nle(4),D-Phe(7)]-alpha-MSH(4--10), a pseudo-peptide analogue of alpha-melanocyte stimulating hormone (alpha-MSH) linked to a thiol-reactive phospholipid. With these complexes we obtained an up to 70-fold increase of transfection with B16-F1 melanoma cells. However when B16-G4F, an alpha-MSH receptor negative melanoma cell line was transfected, an up to 700-fold increased transfection efficiency was observed. The peptide hormone analogue was equally efficient when it was only mixed with lipospermine--DNA complexes without covalent coupling. In addition to melanoma cells we also obtained up to 30-fold increased transfection with BN cells (embryonic liver cells). Our data show that an alpha-MSH analogue increased transfection independently of the MSH receptor expression but reaches efficiencies approaching those obtained with peptides derived from viral fusion proteins. The absence of targeting of constructs containing [Nle(4),D-Phe(7)]-alpha-MSH(4-10) can probably be attributed due to the relatively modest number of MSH receptors at the surface of melanoma. We suggest, however, that the peptide hormone analogue used in this study has membrane-active properties and could be of interest as helper agent to enhance non-viral gene delivery presumably by endosomal-destabilizing properties.
Sujet(s)
Techniques de transfert de gènes , Spermine/analogues et dérivés , Hormone mélanotrope alpha/analogues et dérivés , Hormone mélanotrope alpha/pharmacologie , Marqueurs d'affinité , Animaux , Chlorates , ADN/composition chimique , Souris , Récepteur hormone hypophysaire/analyse , Spermine/composition chimique , Cellules cancéreuses en culture , Hormone mélanotrope alpha/composition chimiqueRÉSUMÉ
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the vasointestinal polypeptide gene family for which neurotrophic activity has been postulated. PACAP mRNA is expressed in the developing and adult hippocampus, which is the principal target region of septal cholinergic neurons. We therefore studied the effects of PACAP on septal cholinergic neurons. In primary cultures from septum of embryonic and postnatal rats, PACAP increased the number of neurons immunohistochemically stained for the low-affinity nerve growth factor (NGF) receptor p75 and for the enzyme choline acetyltransferase (ChAT). PACAP also caused a corresponding increase in ChAT activity. In comparison, NGF had a greater effect than PACAP on the number of p75- and ChAT-positive neurons in these cultures. In vivo, following fimbria fornix transection, the number of immunohistochemically stained septal cholinergic neurons fell significantly to 18% in rats given continuous intracerebroventricular infusion of vehicle, whereas in rats given NGF the number of these neurons did not differ significantly from unoperated controls. In PACAP-treated rats the number was 48% of unoperated values, which represented a significant increase compared with vehicle-treated rats and a significant decrease compared with NGF-treated rats or unoperated controls. Double-staining experiments revealed that most ChAT-positive neurons in rat medial septum also express PACAP receptor 1. Together the results show that PACAP promotes the survival of septal cholinergic neurons in vitro, and after injury in vivo, suggesting that PACAP acts as a neurotrophic factor influencing the development and maintenance of these neurons.